Xiagem Trio 2 Tablet ER is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. It contains Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg, each contributing distinct mechanisms to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, reducing postprandial hyperglycemia. The extended-release (ER) formulation ensures sustained drug release, promoting better patient compliance and stable plasma concentrations. Xiagem Trio 2 Tablet ER is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It should be used under medical supervision with periodic monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis risk associated with Metformin. Dose adjustments may be necessary based on clinical response and tolerability. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.